U.S. Markets open in 8 hrs 31 mins
  • S&P Futures

    +8.75 (+0.23%)
  • Dow Futures

    +58.00 (+0.19%)
  • Nasdaq Futures

    +40.25 (+0.34%)
  • Russell 2000 Futures

    +4.00 (+0.23%)
  • Crude Oil

    -0.54 (-0.48%)
  • Gold

    +1.30 (+0.07%)
  • Silver

    -0.08 (-0.37%)

    -0.0018 (-0.1681%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +1.41 (+5.23%)

    +0.0014 (+0.1147%)

    -0.0850 (-0.0624%)

    -441.63 (-2.13%)
  • CMC Crypto 200

    -9.76 (-2.17%)
  • FTSE 100

    +65.09 (+0.90%)
  • Nikkei 225

    -273.91 (-1.01%)

Antimicrobial Susceptibility Testing Market to Surpass US$ 5,808.92 Million by 2030 - Coherent Market Insights

·5 min read

SEATTLE, June 21, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global antimicrobial susceptibility testing market is estimated to be valued at US$ 3,525.75 million in 2022 and expected to exhibit a CAGR of 6.4% over the forecast period (2022-2030).

Coherent Market Insights Logo
Coherent Market Insights Logo

Key Trends and Analysis of the Global Antimicrobial Susceptibility Testing Market:

The current industry trends include the adoption of various inorganic strategies by key players in the market, such as acquisitions and agreements to expand their product portfolio.

For instance, in April 2022, BIOMÉRIEUX, a multinational biotechnology company, announced that it had entered into an agreement to acquire Specific Diagnostics, a privately held U.S.-based company that has developed a rapid antimicrobial susceptibility test (AST) system, SPECIFIC REVEAL Rapid AST system that delivers phenotypic AST directly from positive blood cultures.

Moreover, in February 2020, Bio-Rad Laboratories, Inc., a global company involved in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets, acquired Exact Diagnostics, a developer and manufacturer of diagnostic products that help ensure the validity and consistency of test results. With the acquisition of Exact Diagnostics, Bio-Rad Laboratories, Inc. has access to a comprehensive catalogue of molecular quality control products in the areas of transplant, respiratory, virology, microbiology, sexually transmitted infections, and vector-borne diseases.

The increased availability of products based on various technologies is expected to drive the market growth.

For instance, the CE-marked Alfed 60 AST system of Alifax S.r.l. Italy, a company specialized in the development, production, and distribution of automated clinical diagnostic instruments, uses sensitive laser-light scattering technology to detect bacterial growth in a liquid culture broth and provides antimicrobial susceptibility results directly from positive blood culture bottles within 4–6 hours.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2449

Key Market Takeaways:

The global antimicrobial susceptibility testing market is expected to exhibit a CAGR of 6.4% over the forecast period, owing to increasing approval of product. For Instance, in 2020, Accelerate Diagnostics, Inc., an in vitro diagnostics company, announced that the company received the U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to Accelerate Pheno system to improve performance and expand the system's antimicrobial susceptibility testing (AST) menu for bloodstream infections. The new release features improvements in susceptibility testing performance for four important antibiotics used to treat Pseudomonas aeruginosa, as well as the addition of the combination of P. aeruginosa and aztreonam, an empiric antibiotic, to the Accelerate PhenoTest BC kit testing panel.

Among region, North America is expected to exhibit a high growth rate in the global antimicrobial susceptibility testing market during the forecast period, owing to the increasing launches of product. For instance, in 2021, Accelerate Diagnostics, Inc., an in vitro diagnostics company, announced the launch of a new IVD (In vitro diagnostic) configuration of its Accelerate PhenoTest BC kit in the U.S. With this launch, the company now provides two solutions for fast sepsis testing. The new configuration provides fast antimicrobial susceptibility testing (AST) results in around 7 hours direct from positive blood cultures and is designed to run on the Accelerate Pheno system as a flexible solution for laboratories that already have a rapid identification system.

Key players operating in the global antimicrobial susceptibility testing market include Thermo Fisher Scientific Inc. and BIOMÉRIEUX, HiMedia Laboratories, Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd.,Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc., and Zhuhai DL Biotech Co., Ltd.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2449

Detailed Segmentation:

Global Antimicrobial Susceptibility Testing Market, By Product Type:

  • Manual Antimicrobial Susceptibility Testing Products

  • Automated Laboratory Instruments

  • Consumables

Global Antimicrobial Susceptibility Testing Market, By Application:

  • Antibacterial

  • Antifungal

  • Anti-parasitic

  • Antiviral

Global Antimicrobial Susceptibility Testing Market, By Method:

  • Disk Diffusion

  • Rapid Automated AST

  • Broth Dilution

  • Gradient Diffusion

  • Genotypic Methods

Global Antimicrobial Susceptibility Testing Market, By End User:

  • Hospitals

  • Pathology/Diagnostic Laboratories

  • Research and Academic Institutes

  • Pharmaceutical and Biotechnology Companies

  • Contract Research Organizations

Global Antimicrobial Susceptibility Testing Market, By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/2449

Find more related trending reports below:

Automated Antimicrobial Susceptibility Testing Market, By Product Type (Consumables and Instruments), By Detection Method (Turbidimetric and Colorimetric), By Application (Antibacterial (Tuberculosis and Sepsis), Antifungal, Anti-parasitic, and Anti-viral), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals, and Pathology/Diagnostic Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018-2026

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedInTwitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg


View original content:https://www.prnewswire.com/news-releases/antimicrobial-susceptibility-testing-market-to-surpass-us-5-808-92-million-by-2030--coherent-market-insights-301572016.html

SOURCE Coherent Market Insights